Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Rockefeller University
New York, New York
The records below are financial disclosure and conflict of interest records obtained by ProPublica from the National Institutes of Health and dozens of large public universities across the country. The NIH only has records for researchers who seek or receive its funding.
Total Disclosures: 25
| Name | Type | Company | Disclosed Value | Year Filed |
|---|---|---|---|---|
| Michel Nussenzweig | Conflict of Interest | Frontier Biotechnologies | $500,000 - $549,999 | 2018 |
| Michel Nussenzweig | Conflict of Interest | Celldex Therapeutics | $400,000 - $449,999 | 2015 |
| C. David Allis | Conflict of Interest | Constellation Pharmaceuticals | $150,000 - $199,999 | 2014 |
| Michel Nussenzweig | Conflict of Interest | Frontier Biotechnologies | $100,000 - $149,999 | 2018 |
| Tom Tuschl | Conflict of Interest | Regulus Therapeutics | $100,000 - $149,999 | 2013 |
| Tom Tuschl | Conflict of Interest | Regulus Therapeutics | $100,000 - $149,999 | 2013 |
| Michel Nussenzweig | Conflict of Interest | Frontier Biotechnologies | $60,000 - $79,999 | 2018 |
| Paul Greengard | Conflict of Interest | Takeda Pharmaceuticals | $40,000 - $59,999 | 2014 |
| Thomas Tuschl | Conflict of Interest | Regulus Therapeutics | $40,000 - $59,999 | 2015 |
| Thomas Tuschl | Conflict of Interest | Regulus Therapeutics | $20,000 - $39,999 | 2015 |
| Bruce McEwen | Conflict of Interest | Corcept Therapeutics | $20,000 - $39,999 | 2013 |
| Tom Tuschl | Conflict of Interest | Regulus Therapeutics | $20,000 - $39,999 | 2013 |
| Tom Tuschl | Conflict of Interest | Regulus Therapeutics | $20,000 - $39,999 | 2013 |
| Thomas Tuschl | Conflict of Interest | Max Planck | $10,000 - $19,999 | 2015 |
| C. David Allis | Conflict of Interest | Constellation Pharmaceuticals | $10,000 - $19,999 | 2014 |
| C. David Allis | Conflict of Interest | EMP Millipore | $10,000 - $19,999 | 2014 |
| Daniel Gareau | Conflict of Interest | SurgiVance Inc | $10,000 - $19,999 | 2017 |
| Michel Nussenzweig | Conflict of Interest | Celldex Therapeutics | $10,000 - $19,999 | 2015 |
| Tom Tuschl | Conflict of Interest | Max Planck | $10,000 - $19,999 | 2013 |
| C. David Allis | Conflict of Interest | Active Motif | $10,000 - $19,999 | 2014 |
| Tom Tuschl | Conflict of Interest | Max Planck | $10,000 - $19,999 | 2013 |
| Tom Tuschl | Conflict of Interest | Regulus Therapeutics | $0 - $4,999 | 2013 |
| Tom Tuschl | Conflict of Interest | Regulus Therapeutics | $0 - $4,999 | 2013 |
| Thomas Tuschl | Conflict of Interest | Regulus Therapeutics | $0 - $4,999 | 2015 |
| Michel Nussenzweig | Conflict of Interest | Frontier Biotechnologies | $0 - $4,999 | 2018 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.